N-乙基-3-溴苯磺酰胺 | 871269-07-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-3-溴苯磺酰胺
• 中文别名: 3-溴-n-乙基苯磺胺
• 英文名称: 3-bromo-N-ethylbenzenesulfonamide
• CAS: 871269-07-7
• 化学式: C₈H₁₀BrNO₂S
• mdl: MFCD07363819
• 分子量: 264.143
• InChiKey: MADIDEQQKAOBFI-UHFFFAOYSA-N

物化性质

• 熔点：
  46-50

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Ethyl 3-bromobenzenesulfonamide
Product Name:
Synonyms: N-Ethyl 3-bromophenylsulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Ethyl 3-bromobenzenesulfonamide
Ingredient name:
CAS number: 871269-07-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO2S
Molecular weight: 264.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基-3-溴苯磺酰胺 在 四(三苯基膦)钯 、 sodium cyanoborohydride 、 potassium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  发现新型联苯磺酰胺类似物作为 NLRP3 炎症小体抑制剂

  摘要：

  NLRP3 炎症小体的异常激活已在多种人类疾病中观察到。用小分子抑制剂靶向 NLRP3 蛋白作为疾病干预的有效策略显示出巨大的潜力。在此，设计并合成了一系列新型联苯磺酰胺NLRP3炎症小体抑制剂。代表性化合物被鉴定为有效且特异性的 NLRP3 炎性体抑制剂，IC 值为 0.57 μM。初步机制研究表明，该化合物可直接结合NLRP3蛋白（1.15 μM），有效抑制NLRP3炎症小体的组装和激活。小鼠急性腹膜炎模型的结果表明，它能有效抑制 NLRP3 炎症小体通路，证明其抗炎特性。我们的研究结果强烈支持进一步开发用于治疗 NLRP3 相关疾病的潜在先导化合物。

  DOI：

  10.1016/j.bioorg.2024.107263
• 作为产物：
  描述：

  3-溴苯磺酰氯 、 乙胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-乙基-3-溴苯磺酰胺
  参考文献：
  名称：

  发现新型联苯磺酰胺类似物作为 NLRP3 炎症小体抑制剂

  摘要：

  NLRP3 炎症小体的异常激活已在多种人类疾病中观察到。用小分子抑制剂靶向 NLRP3 蛋白作为疾病干预的有效策略显示出巨大的潜力。在此，设计并合成了一系列新型联苯磺酰胺NLRP3炎症小体抑制剂。代表性化合物被鉴定为有效且特异性的 NLRP3 炎性体抑制剂，IC 值为 0.57 μM。初步机制研究表明，该化合物可直接结合NLRP3蛋白（1.15 μM），有效抑制NLRP3炎症小体的组装和激活。小鼠急性腹膜炎模型的结果表明，它能有效抑制 NLRP3 炎症小体通路，证明其抗炎特性。我们的研究结果强烈支持进一步开发用于治疗 NLRP3 相关疾病的潜在先导化合物。

  DOI：

  10.1016/j.bioorg.2024.107263

文献信息

• Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)
  作者：Nicole Mayer、Martina Schweiger、Elisabeth Fuchs、Anna K. Migglautsch、Carina Doler、Gernot F. Grabner、Matthias Romauch、Michaela-Christina Melcher、Rudolf Zechner、Robert Zimmermann、Rolf Breinbauer

  DOI：10.1016/j.bmc.2020.115610

  日期：2020.8

  non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin

  高血清脂肪酸（FA）水平与胰岛素抵抗的发展存在因果关系，胰岛素抵抗最终发展为2型糖尿病和在代谢综合征中普遍存在的非酒精性脂肪肝疾病（NAFLD）。甘油三酸酯脂肪酶（ATGL）是细胞内三酰基甘油（TG）储存液水解的初始酶，可释放从脂肪细胞释放到循环中的脂肪酸。因此，ATGL特异性抑制剂具有降低循环FA浓度并抵消胰岛素抵抗和NAFLD发生的潜力。在本文中，我们报告了鼠ATGL的小分子抑制剂的结构-活性关系（SAR）研究，该研究导致Atglistatin的发展。Atglistatin是鼠ATGL的特异性抑制剂，
• [EN] TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS<br/>[FR] DÉRIVÉS RATTACHÉS DE BENZAMIDE UTILISÉS COMME PUISSANTS INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016028971A1

  公开（公告）日：2016-02-25

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物或其立体异构体、互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Tied-back benzamide derivatives as potent rock inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US10112939B2

  公开（公告）日：2018-10-30

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3183248B1

  公开（公告）日：2020-11-11